Catalogo dei prodotti della ricerca

NOBILI, Valerio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.128
EU - Europa 1.153
AS - Asia 1.079
AF - Africa 34
SA - Sud America 34
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 12.441
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.047
IN - India 451
SG - Singapore 306
SE - Svezia 301
CN - Cina 264
IT - Italia 254
RO - Romania 122
GB - Regno Unito 104
IE - Irlanda 86
CA - Canada 70
DE - Germania 69
UA - Ucraina 68
FI - Finlandia 65
TR - Turchia 38
AR - Argentina 26
TG - Togo 24
BG - Bulgaria 20
NL - Olanda 19
BE - Belgio 10
EU - Europa 8
FR - Francia 8
MX - Messico 8
VN - Vietnam 6
AU - Australia 5
CH - Svizzera 5
DK - Danimarca 5
ES - Italia 4
RU - Federazione Russa 4
SC - Seychelles 4
TW - Taiwan 4
ZA - Sudafrica 4
BZ - Belize 3
CL - Cile 3
GR - Grecia 3
PT - Portogallo 3
BR - Brasile 2
EG - Egitto 2
KZ - Kazakistan 2
MY - Malesia 2
NO - Norvegia 2
PE - Perù 2
PK - Pakistan 2
CO - Colombia 1
EE - Estonia 1
HK - Hong Kong 1
IR - Iran 1
KR - Corea 1
PH - Filippine 1
Totale 12.441
Salva come PNG Salva come JPEG
Città #
Fairfield 2.068
Ashburn 861
Woodbridge 859
Seattle 809
Houston 722
Cambridge 687
Wilmington 619
Chandler 541
Ann Arbor 345
Princeton 272
Millbury 246
Plano 241
Des Moines 164
Singapore 159
Lawrence 150
Beijing 136
San Diego 117
Falls Church 109
Dearborn 106
Rome 103
Dublin 86
Andover 74
Southend 72
Norwalk 59
Toronto 43
Istanbul 38
San Paolo di Civitate 36
Boston 28
Fremont 25
New York 25
Federal 24
Lomé 24
Helsinki 23
Mannheim 22
Ottawa 22
Bühl 21
Sofia 20
San Mateo 18
Redmond 16
Jinan 13
Jacksonville 11
Brussels 10
Buffalo 10
Hefei 10
Linköping 10
Nanjing 10
Birmingham 9
Guangzhou 9
Kunming 9
Phoenix 9
Boardman 8
Laurel 8
Nanchang 8
Shenzhen 8
London 7
San Jose 7
Ho Chi Minh City 6
Bremen 5
Los Angeles 5
Mexico City 5
Redwood City 5
Candelo 4
Chengdu 4
Florence 4
Fuzhou 4
Hangzhou 4
Milan 4
New Taipei City 4
Palermo 4
Provo 4
Riva 4
Shenyang 4
Trumbull 4
Absecon 3
Belize City 3
Boydton 3
Coarezza 3
Foggia 3
Grafing 3
Jönköping 3
Las Vegas 3
Leawood 3
Montréal 3
Muizenberg 3
San Pablo 3
Torino 3
Washington 3
Westminster 3
Xian 3
Zhengzhou 3
Albuquerque 2
Arnsberg 2
Asker 2
Asso 2
Bern 2
Buenos Aires 2
Cairo 2
Changsha 2
Escolca 2
Foshan 2
Totale 10.291
Salva come PNG Salva come JPEG
Nome #
Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease 100
Urinary 1H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment 94
Are children after liver transplant more prone to non-alcoholic fatty liver disease 89
Gut microbiota markers in obese adolescent and adult patients: Age-dependent differential patterns 88
ADAR enzyme and miRNA story: A nucleotide that can make the difference 88
Pediatric liver diseases: current challenges and future perspectives 86
The pharmacological management of NAFLD in children and adolescents 86
Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? 84
Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis 81
Aminotransferases as predictors of mortality 80
Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl 80
Laparoscopic sleeve gastrectomy improves nonalcoholic fatty liver disease-related liver damage in adolescents by reshaping cellular interactions and hepatic adipocytokine production 80
Atherogenic dyslipidemia and cardiovascular risk factors in obese children 78
A 360-degree overview of paediatric NAFLD: recent insights 78
Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease? 77
Liver fibrosis in paediatric liver diseases 76
Insulin resistance and exercise capacity in male children and adolescents with non-alcholic fatty liver disease 76
Redox homeostasis and posttranslational modifications/activity of phosphatase and tensin homolog in hepatocytes from rats with diet-induced hepatosteatosis 73
The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis 73
Metabolic Syndrome and Alcohol Abuse: A Potential Hepatocarcinogenic Mix in Adolescents 73
Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease 73
Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease 73
Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease 72
Nonalcoholic fatty pancreas disease and nonalcoholic fatty liver disease. more than ectopic fat 72
Nonalcoholic Fatty Liver in Children and Adolescents: An Overview 71
The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage 71
Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies 70
Retinol-Binding Protein 4: A Promising Circulating Marker of Liver Damage in Pediatric Nonalcoholic Fatty Liver Disease 70
Paediatric non-alcoholic fatty liver disease: impact on patients and mothers' quality of life 70
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies 69
Diagnostic power of fibroscan in predicting liver fibrosis in nonalcoholic fatty liver disease 69
Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease 69
Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease 68
Treatment of chronic hepatitis c in children. is it necessary and, if so, in whom 68
Metabolic disorders: All that we know from circulating biomarkers 68
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial 68
Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease. double-blind randomised controlled clinical trial 68
Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease 67
Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease 67
Hedgehog/hyaluronic acid interaction network in nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinoma 67
Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children 67
Metabolic syndrome and nonalcoholic steatohepatitis recurrence after liver transplantation in children 66
Biomarkers in nonalcoholic fatty liver disease. a new era in diagnosis and staging of disease in children 66
Unraveling the genetics of fatty liver in obese children: Additive effect of P446L GCKR and I148M PNPLA3 polymorphisms 66
Performance of elf serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease 66
The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease 65
Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach 65
Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment 65
Viral hepatitis in children 65
The Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver Disease 65
Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach 65
null 64
Preemptive liver transplantation in a child with familial hypercholesterolemia 64
Extrahepatic portal vein thrombosis in children and adolescents. influence of genetic thrombophilic disorders 64
Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development 64
The use of ultrasound in clinical setting for children affected by NAFLD. is it safe and accurate? 64
Insulin dynamics of breast- or formula-fed overweight and obese children 64
The contribution of the adipose tissue-liver axis in pediatric patients with nonalcoholic fatty liver disease after laparoscopic sleeve gastrectomy 64
MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease 63
Toll-like receptor 4. a starting point for proinflammatory signals in fatty liver disease 63
Programming, metabolic syndrome, and nafld. the challenge of transforming a vicious cycle into a virtuous cycle 63
Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets 63
Effect of treatment with polyunsaturated fatty acids on hcv- or diet-induced fatty liver 63
Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis 63
Is there any link between dietary pattern and development of nonalcoholic fatty liver disease in adolescence? An expert review 63
I148M PNPLA3 variant and progressive liver disease: a new paradigm in hepatology 63
Screening of an Echinococcus granulosus cDNA library with IgG4 from patients with cystic echinococcosis identifies a new tegumental protein involved in the immune escape. 62
Human hepatic stellate cells are liver-resident antigen-presenting cells 62
Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage 62
Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review 62
The apoc3 t-455c and c-482t promoter region polymorphisms are not associated with the severity of liver damage independently of pnpla3 i148m genotype in patients with nonalcoholic fatty 62
LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease 62
The wide spectrum of hepatic iron overload 62
Children unresponsive to hepatitis B Virus vaccination also need celiac disease testing 62
null 62
Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease 61
Supplementation of monounsaturated and polyunsaturated fatty acids in non-alcoholic fatty liver disease and metabolic syndrome 61
Use of metformin in pediatric age 61
Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease 61
Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease 61
Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis 60
Metformin use in children with nonalcoholic fatty liver disease. an open-label, 24-month, observational pilot study 60
Pediatric post-transplant metabolic syndrome: new clouds on the horizon 60
Association between nocturnal blood pressure dipping and insulin resistance in children affected by NAFLD 60
T regulatory cell number and function: the autoimmune traits in liver diseases 60
null 59
Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children 59
null 58
PNPLA3 I148M polymorphism and liver damage in obese children 58
Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal 58
null 58
Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease 58
Nonalcoholic fatty liver disease and atherosclerosis. 57
LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease 57
Liver fibrosis and therapeutic strategies: the goal for improving metabolism 57
Fatty liver in adolescents: Mechanisms, clinical features and therapy 57
null 57
null 57
Non-alcoholic fatty liver disease in children and adolescents 56
Insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLF) in obese paediatric patients. 56
Totale 6.728
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.117
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.117
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.231 520 124 47 242 505 446 700 516 523 276 181 151
2020/20211.196 108 165 49 45 20 45 23 96 172 179 75 219
2021/20222.498 20 96 212 153 378 171 50 296 219 150 183 570
2022/20231.896 514 297 29 177 204 298 24 96 163 13 57 24
2023/2024796 93 143 38 58 42 46 18 38 4 125 76 115
2024/202574 74 0 0 0 0 0 0 0 0 0 0 0
Totale 13.272